Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 10th International Conference on Ophthalmology and Optometry Beijing, China.

Day 1 :

Keynote Forum

J.T Lin

CEO, New Vision Inc. (Taipei)

Keynote: The 30-year Progress of Vision Laser Technology

Time : 9:30

OMICS International Ophthalmology Conference 2017  International Conference Keynote Speaker J.T Lin photo

Jui-Teng Lin has completed his PhD in Physics from the University of Rochester in USA. He is currently the Chairman and CEO of New Vision Inc., and the Visiting Professor at HE Medical University in China. He is the Editor in Chief of the Medical Device Diagnosis and Engineer. He has served as a Visiting Professor at National Chao Tung University and an Associate Professor at the University of Central Florida. He holds over 45 patents and is the Inventor of flying spot LASIK procedure. He has published over 55 book chapters and over 150 peer review journal papers including 75 SCI-impacted papers.



This overview presentation consists of a historical review of the 30 years progress of laser vision corrections (1987 to 2016), summary of eye lasers and their applications, recent developments and new trends, the principles and formulas of laser and non-laser vision corrections and UV-light-initiated corneal collagen crosslinking. The first human trial of PRK was conducted by Dr. Trokel in 1987, based upon the IBM patent and the animal study in 1983. FDA approved PRK in 1995. The flying-spot scanning technology was invented by Dr. J.T. Lin in 1992 (US patent) who also introduced the customized procedure in 1996. The waveguide device was commercialized in 1999. FDA approved LASIK in 2002. During 1995-1999, various laser systems/procedures were developed including LTK (using Ho:YAG); DTK (using diode laser), RF and CK designed for hyperopia corrections; slide state lasers (YAG-213 nm for PRK), YAG pico-second-PRK, Mini-Excimer for PRK, etc. Technologies developed in the 2000’s include eye-tracking device, microkeratome, elevation map, topography-guided LASIK, wavefront for customized LASIK, presbyopia treatment using SEB and laser scleral-ablation for presbyopia; accommodative IOL. More recently, femto-second lasers are developed for flat cutting and stroma ablation and cataract. UV-light and Riboflavin activated corneal cross linking (CXL) has been developed for clinical use for various corneal deceases such as corneal keratoconus, corneal keratitis, corneal ectasia, corneal ulcers and thin corneas prior to LASIK vision corrections. Combined technology of CXL-PRK, CXL-intra stroma-femto-laser pocket, CXL-phakic-IOL and CXL-IC-ring.

Keynote Forum

Ying Li

Chief Physician

Keynote: Progress of TransPRK and Smile

Time : 10:10

OMICS International Ophthalmology Conference 2017  International Conference Keynote Speaker  Ying Li photo

Ying Li is the Chief Physician and Tutor of Doctoral students at the Department of Ophthalmology in the Chinese Medical Association and the Deputy Head of the Corneal Disease Group. He is the Member of the Asian Dry Eye Institute and Director of Corneal Myopia Laser Surgery Center at the Peking Union Medical College Hospital.


We will present two parts: (A) TransPRK (TPRK) and (B) SMILE clinical outcomes. Part (A) regards to the long term result of TransPRK focusing on its efficacy and safety. This is a retrospective study, 48 patients treating with TPRK and 34 patients with LASEK were followed up for 6 months to 1 year summary. TPRK can correct myopia and astigmatism with high safety and efficacy; comparing to LASEK, TPRK has the advantages of faster epithelium healing and visual recovery, while both achieve great VA. Part (B) presents the study on SMILE clinical outcomes, where a total of 1000 eyes were conducted and 240 eyes having a following up of more than 6 months. The result showed that after surgery, all of the eyes achieved the pre-op best-corrected visual acuity. To evaluate patients’ optical quality following corneal laser refractive surgery, we designed a questionnaire based on National Eye Institute Refractive Error Quality of Life instrument. In SMILE group, patients’ scores were relatively high for these items, indicating rather satisfying surgical outcomes. It can be concluded from the study that the patients’ satisfaction and optical quality were best following SMILE.

OMICS International Ophthalmology Conference 2017  International Conference Keynote Speaker Janardan Kumar photo

Janardan Kumar holds a Ph.D. degree in chemistry under kind supervision of Dr. C. M. Gupta, ex-director, CDRI, Lucknow, India. In the United States, first he received postdoctoral training on motor proteins in the laboratory of Michael P. Sheetz, a lasker award winner, at Duke University Medical Center, North Carolina. He published his work on kinectin, a myocilin like protein, in Science (1995), and an abnormality in myocilin has been predicted to be involved in the pathogenesis of glaucoma.Prior to coming to Becker College, while a research assistant professor at Tufts University, Kumar engineered a new real time perfusion system used for the discovery of drugs to treat glaucoma. Presently, Kumar is chair of the natural sciences department, and is actively engaged in the advancement of course curriculum in microbiology, chemistry, and developing the biotechnology/biology major at Becker College.


Aneurysm mediated release of thrombin into the aqueous humor may be a causative factor of glaucoma.
Janardan Kumar, Becker College, Worcester, USA.
Glaucoma has been known to be associated with ocular hypertension due to age-related dysfunction of outflow pathway tissues. Based on the geometry of outflow pathway tissues, only the inner wall of Schlemm’s canal (SC) cells in the conventional outflow pathway appeared to be arranged as a monolayer consisting of irregular pores. Several studies suggest the biomechanical properties of the endothelial SC cells to be modulators of endothelial barrier function, outflow resistance, and intraocular pressure (IOP). Our studies of thrombin perfusion in enucleated porcine eyes ex-vivo, procured after thorough investigation of unnoticed impurities, revealed an increased outflow resistance. Of significance, as opposed to the effect of thrombin in other cell types for the endothelial barrier function, treatment of thrombin to the human endothelial SC cells monolayer permeability barrier–function assay exhibited a significant decrease in the permeability of horse-radish peroxidase. Even if there was the di-phosphorylated form of myosin light chain that is located in the peripheral region of the cell, formation of stress fibers and focal adhesions were increased significantly, and that resembles the characteristics for the activation of Rho kinase. Such cellular changes of human SC endothelial cells have been correlated with cellular contraction and/or stiffness, causing increased resistance of the outflow. Since the thrombin can cause increased outflow resistance and is known to be involved in increased extra-cellular matrix (ECM) protein deposition and fibrosis, we speculate that release of thrombin in the aqueous humor followed by an aneurysm may be associated with the etiology of glaucoma. Hence, the clinical diagnosis of an aneurysm in glaucomatous patients and detection of thrombin in glaucomatous aqueous humor would provide a better understanding of glaucoma.